Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 22, 2020 08:13 ET | Source: Protara Therapeutics

Protara Therapeutics Announces Pricing of $147.6 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock

NEW YORK, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases...
September 21, 2020 16:01 ET | Source: Protara Therapeutics

Protara Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock

NEW YORK, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases...
September 08, 2020 07:00 ET | Source: Protara Therapeutics

Protara Therapeutics Provides Comparability and U.S. Regulatory Updates for TARA-002 Supporting Advancement in Oncology and Rare Disease Indications

- Company Demonstrates Initial Comparability Between TARA-002 and OK-432, Advancing to Final GMP Comparability Runs - - Reaches Alignment with FDA on Development Path Forward for TARA-002 in...
September 02, 2020 17:49 ET | Source: Protara Therapeutics

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a development-stage clinical biopharmaceutical company developing treatments for rare and specialty diseases...
August 03, 2020 07:00 ET | Source: Protara Therapeutics

Protara Therapeutics Announces Second Quarter 2020 Financial Results and Business Overview

NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a development-stage company developing treatments for rare and specialty diseases with significant unmet needs,...
July 28, 2020 07:00 ET | Source: Protara Therapeutics

Protara Therapeutics Receives Rare Pediatric Disease Designation for TARA-002 for the Treatment of Lymphatic Malformations

NEW YORK, July 28, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet needs,...
July 24, 2020 07:00 ET | Source: Protara Therapeutics

Protara Therapeutics Announces Appointment of Barry P. Flannelly to Board of Directors

NEW YORK, July 24, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet needs,...
July 02, 2020 19:59 ET | Source: Protara Therapeutics, Inc.

CORRECTION – Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, July 02, 2020 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today, Thursday, July 2nd, by Protara Therapeutics, Inc. (Nasdaq: TARA), please note that in the first...
July 02, 2020 16:05 ET | Source: Protara Therapeutics, Inc.

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, July 02, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a development-stage clinical biopharmaceutical company developing treatments for rare and specialty diseases...
June 02, 2020 16:05 ET | Source: Protara Therapeutics, Inc.

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, June 02, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a development-stage clinical biopharmaceutical company developing treatments for rare and specialty diseases...